Cell-free circulating DNA (cfDNA) in plasma has gained global interest as a diagnostic
material for noninvasive prenatal testing and cancer diagnosis, or the so-called “liquid …

Abstract Analysis of patient's materials like cells or nucleic acids obtained in a minimally
invasive or noninvasive manner through the sampling of blood or other body fluids serves as …

Widespread adaptation of liquid biopsy for the early detection of cancer has yet to reach
clinical utility. Circulating tumor DNA is commonly detected though the presence of genetic …

A liquid biopsy is a minimally invasive or non-invasive method to analyze a range of tumor
material in blood or other body fluids, including circulating tumor cells (CTCs), cell-free DNA …

Effective screening modalities are currently available for only a small subset of cancers, and
they generally have suboptimal performance with complicated procedures. Therefore, there …

Molecular analysis of cell-free DNA (cfDNA) that circulates in plasma and other body fluids
represents a “liquid biopsy” approach for non-invasive cancer screening or monitoring. The …

While tissue biopsy has for the longest time been the gold-standard in biomedicine,
precision/personalized medicine is making the shift toward liquid biopsies. Cell-free DNA …

Cell-free DNA (cfDNA) in bodily fluids has rapidly transformed the development of
noninvasive prenatal testing, cancer liquid biopsy, and transplantation monitoring. Plasma …

Cell-free DNA (cfDNA)–based liquid biopsy is a promising approach for the early detection
of cancer. A major hurdle is the limited yield of cfDNA from one blood draw, limiting the use …

There is much global research interest surrounding the use of cell-free DNA (cfDNA) for
liquid biopsies. cfDNA-based non-invasive prenatal testing for foetal chromosomal …